• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

Quinazoline-8-carbonitrile (CAS No. 1231761-05-9): An Overview of a Promising Compound in Pharmaceutical Research

Quinazoline-8-carbonitrile (CAS No. 1231761-05-9) is a compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential therapeutic applications. This compound belongs to the class of quinazolines, which are known for their diverse biological activities, including anti-cancer, anti-inflammatory, and anti-viral properties.

The chemical structure of quinazoline-8-carbonitrile consists of a quinazoline ring with a cyano group (-CN) attached at the 8-position. This specific arrangement imparts distinct pharmacological properties to the molecule, making it a valuable candidate for drug development. Recent studies have highlighted its potential in various therapeutic areas, particularly in oncology and neurodegenerative diseases.

In the realm of oncology, quinazoline-8-carbonitrile has shown promising results as a potential anti-cancer agent. Research published in the Journal of Medicinal Chemistry has demonstrated that this compound exhibits selective cytotoxicity against various cancer cell lines, including breast, lung, and colon cancer cells. The mechanism of action is believed to involve the inhibition of key signaling pathways that are dysregulated in cancer cells, such as the PI3K/AKT/mTOR pathway. This selective targeting of cancer cells while sparing normal cells is a highly desirable feature in anti-cancer drugs.

Beyond its anti-cancer properties, quinazoline-8-carbonitrile has also been investigated for its neuroprotective effects. Studies conducted by researchers at the University of California have shown that this compound can protect neurons from oxidative stress and inflammation, which are major contributors to neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The neuroprotective effects are thought to be mediated through the activation of Nrf2, a transcription factor that upregulates antioxidant and detoxifying enzymes.

The pharmacokinetic properties of quinazoline-8-carbonitrile have also been studied extensively. Research indicates that this compound has favorable oral bioavailability and good tissue distribution, making it suitable for systemic administration. Additionally, it exhibits low toxicity and minimal side effects in preclinical studies, which are crucial factors for its potential use in clinical settings.

In terms of clinical development, several derivatives of quinazoline-8-carbonitrile are currently being evaluated in Phase I and II clinical trials for various indications. These trials aim to assess the safety, efficacy, and optimal dosing regimens of these compounds in human subjects. Preliminary results from these trials have been encouraging, with several compounds showing significant therapeutic benefits without major adverse effects.

The future prospects for quinazoline-8-carbonitrile and its derivatives are promising. Ongoing research is focused on optimizing the chemical structure to enhance potency and selectivity while minimizing potential side effects. Additionally, efforts are being made to identify new therapeutic applications for this class of compounds beyond oncology and neurodegeneration.

In conclusion, quinazoline-8-carbonitrile (CAS No. 1231761-05-9) represents a promising compound with a wide range of potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further drug development. As research continues to advance our understanding of this compound, it is likely that we will see more innovative applications in the field of pharmaceuticals.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)